AI Insight
This study presents a predictive framework to determine whether drug compounds tested in initial high-throughput screens will produce usable potency measurements in subsequent dose-response testing. The researchers found that the ability to quantify potency (quantifiability) is strongly predictable from primary screening data, with screening features being more informative than molecular structure. The predictive models remained robust across different chemical scaffolds and assay types, suggesting that experimental measurability is a distinct, predictable property separate from biological activity.
Why it matters
This approach could significantly improve efficiency in drug discovery by helping researchers better prioritize which compounds to advance to expensive dose-response profiling, potentially reducing costs and accelerating the screening process. By distinguishing between compounds that show activity versus those that will yield quantifiable potency estimates, pharmaceutical companies can allocate their testing resources more effectively.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Abstract: High-throughput drug screening relies on low-cost primary assays to prioritize compounds for more expensive dose-response profiling, where potency is ultimately quantified. Current screening strategies largely focus on identifying compounds that will confirm biological activity on follow-up, implicitly assuming that confirmed activity will also yield a usable potency estimate. However, confirmed biological activity in screening does not necessarily translate into a quantifiable potency, because active compounds can still fail to produce a reportable dose-response estimate. We therefore present a framework for modeling quantifiability, whether follow-up testing will yield a usable potency estimate, as a distinct triage objective from biological activity. Quantifiability was strongly predictable from the preceding low-cost screen, with most predictive information arising from the observed screening features rather than molecular structure. Response-based predictors remained robust on previously unseen chemical scaffolds and generalized across held-out assay-mechanism families, while the probability of successful quantification varied strongly with response amplitude and assay context. These findings establish experimental measurability, distinct from biological activity, as a predictable property of screening outcomes and show that quantifiability-aware triage can improve the allocation of costly dose-response profiling capacity.
Source: Predicting Quantifiability from Primary Screens to Prioritize Dose-Response Profiling